Company news
Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) news
Sonoma Pharmaceuticals, Inc. news releases on 6ix. Latest, Jun 8, 2023: Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation…
Press releases — page 2
Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union
June 7, 2023
Sonoma Pharmaceuticals Introduces Podiacyn, an All Natural, Over-the-Counter Podiatry Product for Daily Foot Care
April 10, 2023
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI North America Conference in Philadelphia
March 27, 2023
Sonoma Pharmaceuticals and MicroSafe Group Announce New EPA Claims and Green Seal Certification for Nanocyn(R) Hospital-Grade Disinfectant
March 1, 2023
Sonoma Pharmaceuticals Reports Third Quarter 2023 Financial Results
February 13, 2023
Sonoma Pharmaceuticals Announces Partnership with Daewoong Pharmaceutical for Distribution of Primocyn Skin Care in South Korea
January 30, 2023
Sonoma Pharmaceuticals and EMC Pharma Announce Department of Defense DAPA Registration for Microcyn(R) Rx Products
January 24, 2023
Sonoma Pharmaceuticals Launches Two New Products Expanding Its Line of Office Dispense Products Exclusively for Dermatologists and Medical Spas
January 3, 2023
Sonoma Pharmaceuticals Reports Second Quarter 2023 Financial Results
November 13, 2022
Sonoma Pharmaceuticals Launches Two New Dermatological Products for Over-The-Counter Use in the United States
October 26, 2022
Sonoma Pharmaceuticals to Exhibit at Upcoming CPHI Conference in Frankfurt, Germany
October 5, 2022
Sonoma Pharmaceuticals Reports First Quarter 2023 Financial Results
August 10, 2022
Sonoma Pharmaceuticals Launches MicrocynVS(R) Line of Products Exclusively for Veterinarian Use and Announces Partnership with DV Medical Supply
August 1, 2022
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2022 Financial Results
July 12, 2022
Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce that U.S. EPA has Added Nanocyn® Hospital-Grade Disinfectant to List N for Use Against COVID-19
May 31, 2022
Sonoma Pharmaceuticals and MicroSafe Group DMCC Announce EPA Approval for Nanocyn® Hospital-Grade Disinfectant in the U.S.
May 2, 2022
Sonoma Pharmaceuticals Launches New Urinary Tract Infection Product Through Distributors in New Zealand, Australia and South Africa
March 29, 2022
Sonoma Pharmaceuticals Reports Third Quarter FY 2022 Financial Results
February 10, 2022
Sonoma Pharmaceuticals Announces Expansion of its Partner Network for Oral and Dental Products in the U.S. and China
January 19, 2022
Sonoma Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference January 10-13, 2022
January 4, 2022
Sonoma Pharmaceuticals Reports Second Quarter FY 2022 Financial Results
November 14, 2021
Sonoma Pharmaceuticals and Dyamed Biotech Announce Expanded Long-Term Partnership for New Territories and Products in Southeast Asia
November 8, 2021
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Been Approved by the Australia TGA with a 15 Second SARS-CoV-2 (COVID-19) Kill Time
October 14, 2021
Sonoma Pharmaceuticals Launches Its First Over-the-Counter Products in the U.S. on Amazon and a New Consumer-Focused Product on Amazon in Europe
September 27, 2021
Sonoma Pharmaceuticals Announces Expanded Dental Care Line with a New Product for Professional Care in the U.S. and a New Product for Professional and Consumer Care in Switzerland
August 18, 2021
Sonoma Pharmaceuticals Reports First Quarter 2022 Financial Results
August 15, 2021
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2021 Financial Results
July 13, 2021
Sonoma Pharmaceuticals and EMC Pharma Announce an Exclusive Partnership to Expand Commercial Channels of the Microcyn®-based Rx Dermatology and Eye Care Products Nationwide
March 30, 2021
Sonoma Pharmaceuticals to Present at Upcoming Spring Virtual Investor Conferences
March 3, 2021
Sonoma Pharmaceuticals Reports Third Quarter FY 2021 Financial Results
February 15, 2021
Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn® Disinfecting Solution is Now Available in Hong Kong and Thailand
January 27, 2021
Sonoma Pharmaceuticals to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
January 10, 2021
Sonoma Pharmaceuticals Announces Partnership with Gabriel Science, LLC For Dental Markets
December 16, 2020
Sonoma Pharmaceuticals and Crown Laboratories Announce an Exclusive Partnership to Launch Microcyn® Technology-Based Anti-Itch Over-the-Counter Products
December 9, 2020
Sonoma Pharmaceuticals Reports Second Quarter FY 2021 Financial Results
November 19, 2020
Sonoma Pharmaceuticals and MicroSafe Group Announce that Health Canada Authorized Nanocyn® Disinfectant & Sanitizer to be Sold in Canada as a Hard-Surface Disinfectant under COVID-19 Interim Measure
September 16, 2020
Sonoma Pharmaceuticals and Te Arai BioFarma Announce Launch of Two New Microcyn® Technology Products in Australia – Nasocyn® Nasal Care and Oracyn® Oral Care
September 8, 2020
Sonoma Pharmaceuticals Reports First Quarter 2021 Financial Results
August 13, 2020
Sonoma Pharmaceuticals and MicroSafe Group Announce That Microsafe® Disinfectant & Sanitizer Manufactured Using Sonoma’s Microcyn® Technology Successfully Passed Material Compatibility Testing for Both Airbus and Boeing Commercial Transport Aircraft
July 27, 2020
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2020 Financial Results
July 9, 2020
Sonoma Pharmaceuticals and MicroSafe Group Announce that Nanocyn® Disinfectant & Sanitizer Has Received Approval to Be Entered Into the Australian Register of Therapeutic Goods (ARTG) for use against COVID-19
May 27, 2020
Sonoma Pharmaceuticals Announces Expanded Distribution Agreement with Brill International S.L. for Europe and approval of new CE Marking for Microdacyn60® Eye Care
May 25, 2020
Sonoma Pharmaceuticals Announces Asset Purchase Agreement with Middle East Partner MicroSafe Group
February 26, 2020
Sonoma Pharmaceuticals Reports Third Quarter FY 2020 Financial Results
February 13, 2020
Sonoma Pharmaceuticals Engages Maxim Group LLC to Explore Strategic Opportunities for its U.S. Dermatology Division
January 22, 2020
Sonoma Pharmaceuticals Announces Closing of $1.6 Million Public Offering of Common Stock
November 28, 2019
Sonoma Pharmaceuticals Announces Pricing of Approximately $1.6 million Public Offering of Common Stock
November 25, 2019
Sonoma Pharmaceuticals Announces Proposed Public Offering of Common Stock
November 24, 2019
Sonoma Pharmaceuticals Reports Second Quarter FY 2020 Financial Results
November 13, 2019
Sonoma Pharmaceuticals Announces Management Changes
September 30, 2019